| __timestamp | HUTCHMED (China) Limited | Novo Nordisk A/S |
|---|---|---|
| Wednesday, January 1, 2014 | 19764000 | 74244000000 |
| Thursday, January 1, 2015 | 67426000 | 91739000000 |
| Friday, January 1, 2016 | 59752000 | 94597000000 |
| Sunday, January 1, 2017 | 65383000 | 94064000000 |
| Monday, January 1, 2018 | 70165000 | 94214000000 |
| Tuesday, January 1, 2019 | 44738000 | 101933000000 |
| Wednesday, January 1, 2020 | 39457000 | 106014000000 |
| Friday, January 1, 2021 | 97894000 | 117142000000 |
| Saturday, January 1, 2022 | 115306000 | 148506000000 |
| Sunday, January 1, 2023 | 453552000 | 196496000000 |
| Monday, January 1, 2024 | 245881000000 |
Unlocking the unknown
In the ever-evolving landscape of the pharmaceutical industry, understanding the financial health of key players is crucial. This analysis delves into the gross profit trends of Novo Nordisk A/S and HUTCHMED (China) Limited from 2014 to 2023. Over this period, Novo Nordisk A/S consistently outperformed HUTCHMED, with its gross profit peaking at nearly 200 billion in 2023, marking a staggering 165% increase from 2014. In contrast, HUTCHMED's growth trajectory, while positive, was more modest, culminating in a gross profit of approximately 454 million in 2023, a 2,195% increase from its 2014 figures. This stark contrast highlights Novo Nordisk's dominant market position and robust financial strategies. As the industry continues to grow, these insights provide a window into the competitive dynamics shaping the future of pharmaceuticals.
Key Insights on Gross Profit: Novo Nordisk A/S vs Sanofi
Gross Profit Comparison: Novo Nordisk A/S and United Therapeutics Corporation Trends
Gross Profit Analysis: Comparing Novo Nordisk A/S and Dr. Reddy's Laboratories Limited
Gross Profit Analysis: Comparing Novo Nordisk A/S and BioMarin Pharmaceutical Inc.
Novo Nordisk A/S and Catalent, Inc.: A Detailed Gross Profit Analysis
Key Insights on Gross Profit: Novo Nordisk A/S vs Walgreens Boots Alliance, Inc.
Gross Profit Trends Compared: Novo Nordisk A/S vs Bausch Health Companies Inc.
SG&A Efficiency Analysis: Comparing Novo Nordisk A/S and HUTCHMED (China) Limited
Key Insights on Gross Profit: Takeda Pharmaceutical Company Limited vs HUTCHMED (China) Limited
Gross Profit Trends Compared: Incyte Corporation vs HUTCHMED (China) Limited
Gross Profit Trends Compared: Corcept Therapeutics Incorporated vs HUTCHMED (China) Limited
HUTCHMED (China) Limited and Travere Therapeutics, Inc.: A Detailed Gross Profit Analysis